Tuesday, September 22, 2026
ExploreSearch
Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· January 12, 2026

BioNTech präsentiert auf der 44. J.P. Morgan Healthcare-Konferenz Updates zur Geschäftsentwicklung und Schwerpunkte für das Jahr 2026

View original at globenewswire.com
BioNTech präsentiert auf der 44. J.P…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • BioNTech plans to start six additional Phase 3 clinical trials in 2026, bringing total expected Phase 3 trials to 15 by year-end

    80% confidence

  • BioNTech currently expects no revenues from oncology product sales in 2026

    80% confidence

  • 2026 is a year when scientific progress becomes tangible results for BioNTech, with milestones including late-stage data releases, early clinical trial results for combination therapies, and launch of additional Phase 3 trials

    80% confidence

  • BioNTech has positioned itself as a biopharmaceutical company with multiple programs in late-stage clinical development

    80% confidence

  • BioNTech closed 2025 with strong momentum through consistent execution in R&D, partnerships, acquisitions, and strong financial position while advancing next wave of innovations including combination studies

    80% confidence

  • BioNTech expects collaboration revenues from Bristol Myers Squibb partnership in 2026 to be essentially at 2025 levels

    80% confidence

  • BioNTech expects moderate decline in Comirnaty revenues in 2026 compared to 2025, reflecting current COVID-19 vaccine market dynamics influenced by changing vaccination recommendations especially in the United States and transition from multi-year contracts to private markets

    80% confidence

  • Positive clinical trial results could pave the way for multiple short- and medium-term product launches, bringing BioNTech closer to helping patients with various cancer types

    80% confidence

  • BioNTech expects at least 17 late-stage clinical data readouts through 2030 and beyond, including from registration-enabling studies, to inform decisions on multiple potential product launches and establish BioNTech as a multi-product oncology company by 2030

    80% confidence

Data points we hold from this source

BioNTech SE · phase 2 3 trials count25 trials
BioNTech SE · combination therapy trials count10 trials
BioNTech SE · phase 3 trials count15 trials
BioNTech SE · cash17.2 billion_EUR
BioNTech SE · revenue2.6-2.8 billion_EUR

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Frontier AI Slowdown Call Splits Industry, Rattles Capex-Sensitive Markets
Anthropic's Dario Amodei publicly called for a coordinated global slowdown in frontier AI development, a stance Microsoft echoed with a 'humanist' AI code of conduct, but Nvidia and Meta's CEOs rejected any coordinated pause days later, exposing a widening rift between safety-focused and growth-focused AI leaders. The dispute landed amid growing financial scrutiny of AI infrastructure spending — a hyperscaler capex analysis, FTC warnings against antitrust waivers for AI firms, and an 8.6% single-day stock drop in GE Vernova tied directly to the slowdown remarks — signaling investors are newly nervous about whether the AI capex boom (including Alphabet's projected $701B revenue narrative) can be justified if the pace of development itself becomes contested.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Berkshire Hathaway
Both facts report Berkshire Hathaway's cash position on 2026-01-01 with identical observation timestamps, but claim vastly different values: 380 billion USD vs 400 USD. These cannot both be true for the same entity at the same point in time. The magnitude of the discrepancy (a factor of ~10^9) rules out rounding, unit conversion, or methodological differences.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,983
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,983 facts checked against source5,304 source documents archived
Query this data → isubstrate.com
BioNTech präsentiert auf der 44. J.P. Morgan Healthcare-Konferenz Updates zur Geschäftsentwicklung und Schwerpunkte für das Jahr 2026 — Source | Via News | Via News